1-deoxy-D-psicose | 91547-27-2

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 脂肪酰基
• 英文名称: 1-deoxy-D-psicose
• 英文别名: D-1-deoxy-psicose；1-deoxy-D-ribo-[2]hexulose；D-ribo-3,4,5,6-Tetrahydroxy-hexan-2-on；1-Desoxy-D-ribo-[2]hexulose；1-Desoxy-D-psicose；1-deoxy D-psicose；Methylribose；(3R,4R,5R)-3,4,5,6-tetrahydroxyhexan-2-one
• CAS: 91547-27-2
• 化学式: C₆H₁₂O₅
• 分子量: 164.158
• InChiKey: IXDZFGATLNCIOI-NGJCXOISSA-N

物化性质

• 熔点：
  99-100 °C
• 沸点：
  455.3±45.0 °C(Predicted)
• 密度：
  1.417±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  -2.6
• 重原子数：
  11
• 可旋转键数：
  4
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.83
• 拓扑面积：
  98
• 氢给体数：
  4
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  1-deoxy-D-psicose 在 immobilized D-tagatose-3-epimerase 作用下， 以 水 为溶剂， 反应 12.0h， 以75%的产率得到(3S,4R,5R)-3,4,5,6-四羟基己烷-2-酮
  参考文献：
  名称：

  Conversion of l-rhamnose into ten of the sixteen 1- and 6-deoxyketohexoses in water with three reagents: d-tagatose-3-epimerase equilibrates C3 epimers of deoxyketoses

  摘要：

  The efficient isomerization of L-rhamnose [the only cheaply available deoxy hexose] to 1-deoxy-L-psicose, 1-deoxy-D-psicose, 1-deoxy-L-fructose, 1-deoxy-D-fructose, 1-deoxy-L-tagatose, 6-deoxy-L-psicose, 6-deoxy-D-psicose, 6-deoxy-L-fructose, 6-deoxy-D-fructose, and 6-deoxy-L-tagatose is described. The conversion of rhamnose to ten of the sixteen 1- and 6-deoxyketohexoses is accomplished in water in three steps. The range of substrates for D-tagatose-3-epimerase (DTE) is extended to 1- and 6-deoxyketoses. An authentic sample of 6-deoxy-D-psicose is prepared from D-psicose. (C) 2009 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.tetlet.2009.12.024
• 作为产物：
  描述：

  (Z)-1,3,4-trideoxy-5,6-O-isopropylidene-D-glycero-hex-3-eno-2-ulose 在 四氧化锇 、 potassium chlorate 、 溶剂黄146 作用下， 以 甲醇 、 水 为溶剂， 生成 1-deoxy-D-psicose
  参考文献：
  名称：

  A new synthesis of 1-deoxy-d-psicose and 1-deoxy-d-tagatose

  摘要：

  DOI：

  10.1016/0008-6215(85)85231-9

文献信息

• DEOXYKETOHEXOSE ISOMERASE AND METHOD FOR PRODUCING DEOXYHEXOSE AND DERIVATIVE THEREOF USING SAME
  申请人：Izumori Ken

  公开号：US20100105885A1

  公开（公告）日：2010-04-29

  Providing 1- or 6-deoxy products corresponding to all of aldohexoses, ketohexoses and sugar alcohols, as based on Deoxy-Izumoring, as well as a method for systematically producing those products. A method for producing deoxyketohexose and a derivative thereof using a deoxyketohexose isomerase derived from Pseudomonas cichorii ST-24 (FERM BP-2736), comprising epimerizing 1-deoxy D-ketohexose or 6-deoxy D-ketohexose or 1-deoxy L-ketohexose or 6-deoxy L-ketohexose at position 3 to produce the individually corresponding 1-deoxy D-ketohexose or 6-deoxy D-ketohexose or 1-deoxy L-ketohexose or 6-deoxy L-ketohexose as an intended product.

  提供对应于所有己醛糖、己酮糖和糖醇的1-或6-去氧产物，基于去氧-Izumoring，以及一种系统生产这些产物的方法。一种使用来自Pseudomonas cichoriiST-24（FERM BP-2736）的去氧己酮糖异构酶生产去氧己酮糖及其衍生物的方法，包括将1-去氧D-己酮糖或6-去氧D-己酮糖或1-去氧L-己酮糖或6-去氧L-己酮糖在3号位置上对映异构化为各自对应的1-去氧D-己酮糖或6-去氧D-己酮糖或1-去氧L-己酮糖或6-去氧L-己酮糖作为预期产物。
• Antiviral nucleosides
  申请人：Sarma Keshab

  公开号：US20070232562A1

  公开（公告）日：2007-10-04

  Compounds having the formula I wherein R 1 is as herein defined are Hepatitis C virus NS5b polymerase inhibitors. Also disclosed are compositions and methods for inhibiting hepatitis replication, processes for making the compounds and synthetic intermediates used in the process

  具有公式I的化合物，其中R1如本文所定义，是丙型肝炎病毒NS5b聚合酶抑制剂。还公开了用于抑制肝炎复制的组合物和方法，制备化合物的工艺以及工艺中使用的合成中间体。
• Anti-viral nucleosides
  申请人：Martin Armstrong Joseph

  公开号：US20060040890A1

  公开（公告）日：2006-02-23

  4-Amino-1-((2R,3S,4S,5R)-5-azido-3,4-dihydroxy-5-hydroxymethyl-tetrahydro-furan-2-yl)- 1 H-pyrimidin-2-one (I:R 1 =R 2 =R 3 =R 4 =H) and prodrugs thereof are hepatitis C(HCV) polymerase inhibitors. Also disclosed are compositions and methods for inhibiting HCV and treating HCV-mediated diseases, processes for making the compounds and synthetic intermediates employed in the process.

  4-氨基-1-((2R,3S,4S,5R)-5-偶氮基-3,4-二羟基-5-羟甲基-四氢呋喃-2-基)-1H-嘧啶-2-酮（I:R1=R2=R3=R4=H）及其前药是丙型肝炎病毒（HCV）聚合酶抑制剂。还公开了用于抑制HCV和治疗HCV介导的疾病的组合物和方法，以及用于制备这些化合物和用于该过程中使用的合成中间体的方法。
• BRIDGED BICYCLIC NUCLEOSIDES
  申请人：MIRAGEN THERAPEUTICS, INC.

  公开号：US20160010090A1

  公开（公告）日：2016-01-14

  The present invention relates to 2′-C-Bridged Bicyclic Nucleosides and Nucleotides, and oligonucleotides comprising at least one 2′-C-Bridged Bicyclic Nucleotides. The present invention further provides pharmaceutical compositions comprising the nucleosides, nucleotides, and oligonucleotides, as well as their respective methods of use and synthesis.

  本发明涉及2'-C-桥接双环核苷和核苷酸，以及包含至少一个2'-C-桥接双环核苷的寡核苷酸。本发明还提供包含这些核苷、核苷酸和寡核苷酸的药物组合物，以及它们各自的使用和合成方法。
• Alkyl 2--propionates, nucleoside inhibitors of HCV RNA-polymerase NS5B, methods for preparation and use thereof
  申请人：IVACHTCHENKO Alexandre Vasilievich

  公开号：US20160031927A1

  公开（公告）日：2016-02-04

  Compounds of the general formula 1, stereoisomers, pharmaceutically acceptable salts, and/or hydrates, solvates or crystalline forms thereof wherein R 1 represents C 1 -C 4 alkyl; R 2 and R 3 represents fluoro, or R 2 represents fluoro, and R 3 represents methyl; R 4 and R 5 represents hydrogen, or R 4 represents C 1 -C 6 acyl, and R 5 represents hydrogen, or R 4 represents hydrogen, and R 5 represents C 1 -C 6 acyl, or R 4 represents optionally substituted α-aminoacyl, and R 5 represents hydrogen, or R 4 represents hydrogen, and R 5 represents optionally substituted α-aminoacyl; R 6 represents hydrogen, methyl, methoxy or halogen.

  通式1的化合物，立体异构体，药学上可接受的盐，和/或水合物，溶剂合物或结晶形式，其中R1代表C1-C4烷基；R2和R3代表氟，或R2代表氟，R3代表甲基；R4和R5代表氢，或R4代表C1-C6酰基，R5代表氢，或R4代表氢，R5代表C1-C6酰基，或R4代表可选择取代的α-氨基酰基，R5代表氢，或R4代表氢，R5代表可选择取代的α-氨基酰基；R6代表氢，甲基，甲氧基或卤素。